Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Advertisement

Advertisement




May
17
Today In Oncology
FDA Approves Atezolizumab for Adjuvant Treatment of MRD-Positive MIBC
Sigmoidoscopy Reduces CRC Incidence Rates in Men in Norwegian Screening Study
Early Ovarian Cancer Minimally Invasive Surgery, Intraoperative Capsule Rupture, and Survival
Local Salvage Therapy for Post-Radiotherapy Local Recurrence of Prostate Cancer
Study Finds DLBCL Subtype May Have Higher Mortality Risk in Female Patients
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo